Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, reported that the randomized, double-blind, placebo-controlled TOURMALINE-MM1 pivotal phase III trial evaluating the safety and efficacy of ixazomib, the first oral proteasome inhibitor, conducted in patients with relapsed or refractory multiple myeloma (MM) achieved its primary endpoint of improving progression-free survival at the first pre-specified interim analysis.